Holdings in Company

RNS Number : 1838C

Novacyt S.A.

18 February 2022

 

Novacyt S.A.

("Novacyt" or the "Company")

Holdings in Company

Paris, France and Camberley, UK - 18 February 2022 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex SA ("Biosynex") on 18 February 2022 that, as at 14 February 2022, Biosynex's holding in the Company on a voting and capital basis is 4.04% (2,855,959 shares).

For further information, please refer to   www.novacyt.com   or contact:

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] / [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

[phone]

[e-mail] / [e-mail] / [e-mail]  

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]  

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com  

website: www.novacyt.com

 

END

 

 

HOLUWVVRUBUUAAR